• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Biocon receives 12 USFDA observations for Malaysia unit

biospectrumasiaJuly 10, 2019

Tag:

Indian biopharmaceutical company Biocon has announced that its Sdn Bhd’s Insulin Glargine Drug Substance, Drug Product and Device assembly facilities in Malaysia underwent a pre-approval inspection by the U.S. FDA between June 24 and July 5, 2019. The inspection across these 3 units concluded with 12 observations issued on the Form 483.

The company will respond to the FDA with a Corrective and Preventive Action Plan and are confident of addressing these observations expeditiously. Biocon does not expect any change to its commercialization plans for Insulin glargine in the U.S. Biocon remains committed to global standards of Quality and Compliance.

Previous:NUS opens new centre for oral health

Next:DTC genetic testing market size to exceed $2.5bn by 2025

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Biocon receives 12 USFDA observations for Malaysia unit | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

CEFPROZIL

CEFPROZIL
Cobalt-aluminum alloy (noble metal catalyst series)

Cobalt-aluminum alloy (noble metal catalyst series)
Sgxg-1/2 automatic revolving cover machine

Sgxg-1/2 automatic revolving cover machine
2,4-Dichlorobenzo[4,5]thieno[3,2-d]pyrimidine

2,4-Dichlorobenzo[4,5]thieno[3,2-d]pyrimidine
Amoxicillin USP/EP 98%min supplier Pharmaceutical API Antibiotics Penicillin A broad-spectrum antibi

Amoxicillin USP/EP 98%min supplier Pharmaceutical API Antibiotics Penicillin A broad-spectrum antibi
3-Aminophthalimide

3-Aminophthalimide
L-Lysine Acetate

L-Lysine Acetate
Cephalexin Impurity 1

Cephalexin Impurity 1
Scutellaria Baicalensis Root Extract Powder Baicalin

Scutellaria Baicalensis Root Extract Powder Baicalin
Dynorphin A (1-13) Acetate

Dynorphin A (1-13) Acetate

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service